# Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VIS649 (Sibeprenlimab), an APRIL-Neutralizing IgG2 Monoclonal Antibody, in Healthy Volunteers

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/safety-tolerability-pharmacokinetics-and-pharmacodynamics-of-vis649/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Mohit Mathur,Jonathan Barratt,Yusuke Suzuki,Frank Engler,Marcela F. Pasetti,Jill Yarbrough,Susan Sloan,David Oldach |
| Citations | 45 |
| DOI | 10.1016/j.ekir.2022.01.1073 |
| Fields | Medicine |
| Open Access | true |
| OA Status | gold |
| OA URL | https://doi.org/10.1016/j.ekir.2022.01.1073 |
| OpenAlex ID | https://openalex.org/W4210849595 |
| PMID | 35570983 |
| Type | article |
| Year | 2022 |

## Paper authors

- [Mohit Mathur](https://scholariq.org/researchers/mohit-mathur/)

## Paper journal

- [Kidney International Reports](https://scholariq.org/journals/kidney-international-reports/)

## Paper primary topic

- [Renal Diseases and Glomerulopathies](https://scholariq.org/topics/renal-diseases-and-glomerulopathies/)

## Paper topics

- [Renal Diseases and Glomerulopathies](https://scholariq.org/topics/renal-diseases-and-glomerulopathies/)
- [Renal Transplantation Outcomes and Treatments](https://scholariq.org/topics/renal-transplantation-outcomes-and-treatments/)
- [Monoclonal and Polyclonal Antibodies Research](https://scholariq.org/topics/monoclonal-and-polyclonal-antibodies-research/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.